Sumitomo Mitsui Trust Group
RPTX

Sumitomo Mitsui Trust Group’s Repare Therapeutics RPTX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-116,249
Closed -$162K – 1079
2025
Q2 		$162K Hold
116,249
– – ﹤0.01% 1024
2025
Q1 		$115K Hold
116,249
– – ﹤0.01% 1028
2024
Q4 		$152K Sell
116,249
-132,966
-53% -$396K ﹤0.01% 1037
2024
Q3 		$857K Sell
249,215
-27,953
-10% -$92K ﹤0.01% 909
2024
Q2 		$915K Sell
277,168
-31,281
-10% -$112K ﹤0.01% 906
2024
Q1 		$1.45M Sell
308,449
-17,562
-5% -$113K ﹤0.01% 928
2023
Q4 		$2.38M Hold
326,011
– – ﹤0.01% 887
2023
Q3 		$3.94M Buy
326,011
+3,395
+1% +$35K ﹤0.01% 852
2023
Q2 		$3.41M Buy
322,616
+161,018
+100% +$1.66M ﹤0.01% 865
2023
Q1 		$1.59M Sell
161,598
-12,435
-7% -$143K ﹤0.01% 941
2022
Q4 		$2.56M Sell
174,033
-13,004
-7% -$195K ﹤0.01% 908
2022
Q3 		$2.27M Buy
+187,037
New +$2.41M ﹤0.01% 928

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RPTX Position: Q3 2025 in Review

Sumitomo Mitsui Trust Group sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 116,249 shares — an estimated $162K sold.

Sumitomo Mitsui Trust Group first reported a position in RPTX in Q3 2022 and held it in 12 quarters. The position peaked at $3.94M in Q3 2023. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.

  • Sumitomo Mitsui Trust Group reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 116,249 Repare Therapeutics shares in Q3 2025, an estimated $162K.
  • Sumitomo Mitsui Trust Group first reported a position in Repare Therapeutics in Q3 2022 and held it in 12 quarters.
  • Sumitomo Mitsui Trust Group's Repare Therapeutics position peaked at $3.94M in Q3 2023.
  • 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2025, filed 27 Oct 2025.